ESTRO 2025 - Abstract Book

S4164

RTT - Patient experience and quality of life

ESTRO 2025

Conclusion: These findings demonstrate successful use of PROMs to identify late toxicities up to 5.5 years following chemoradiation for anal cancer. The response rate achieved here suggests potential for future PROMs-led long-term follow-up and toxicity management.

Keywords: PROMs, Anal cancer, Late toxicity

References: 1. Pelvic Radiation Disease Association (PRDA) (2022) Best practice pathway for pelvic radiation disease. Available at: https://www.prda.org.uk/wp-content/uploads/2022/09/PRDA_Best-Practice-Pathway_Toolkit.pdf 2. Tom, A., Bennett, A.V., Rothenstein, D., Law, E. and Goodman, K.A. (2017) ‘Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy in anal cancer’, Quality of Life Research , 27(1), pp. 91-103. 3. Kronborg, C., Serup-Hansen, E., Lefèvre, A., Wilken E.E, Petersen, J.B., Hansen J., et al. (2018) ‘Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization’, Radiotherapy and Oncology , 128(2), pp. 375-379.

1397

Digital Poster MANIV Breath-hold in clinical routine : Enhancing Patient Experience thanks to Physiotherapist guidance Nicolas Audag 1,2,3 , Ana Francisca Neves Marques 4 , Genevieve Van Ooteghem 5,6 1 Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL (airways) & Dermatologie (skin), Groupe Recherche en Kinésithérapie Respiratoire, Université Catholique de Louvain, Brussels, Belgium. 2 Service de kinésithérapie et ergothérapie, Cliniques universitaires Saint-Luc, Brussels, Belgium. 3 Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium. 4 Service de radiothérapie oncologique, Cliniques universitaires Saint-Luc, Brussels, Belgium. 5 Institut de Recherche Expérimentale et Clinique (IREC), Molecular Imaging Radiotherapy and Oncology (MIRO), Université Catholique de Louvain, Brussels, Belgium. 6 Service de Radiothérapie oncologique, Cliniques universitaires Saint-Luc, Brussels, Belgium Purpose/Objective: Mechanically-assisted non-invasive ventilation (MANIV) is used to help unsedated patients to perform repeated breath-holds (BH) of 30 seconds during abdominal stereotactic ablative radiotherapy (SABR). This technique allows for a PTV margin reduction and OARs sparing [1-3]. Since this technique is still in its early stages, gaining a better understanding of patients experience will enhance patient support and the overall process. This study assessed the experience of patients treated with MANIV-BH. Material/Methods: The feedback from patients who underwent SABR with MANIV for liver or pancreatic cancers were collected through a telephone survey. Before treatment, patients underwent a single coaching session performed by an experienced physiotherapist. He was responsible for setting the ventilation parameters required to achieve successive 30sec BHs via an oronasal mask. Subsequently, patients had their 5 SABR sessions with identical ventilation parameters. Questionnaires evaluated the ease of execution, understanding, and comfort on a 10-points Likert scale for the coaching and treatment sessions. Patients were also asked if they experienced any stress. A McNemar test compared the proportion of patients reporting stress. Finally, patients were asked if they would be willing to undergo MANIV again if necessary. Results: Among the 21 patients treated since December 2023, 6 did not answer their phones, 2 died from disease progression, one declined to participate, and 12 (3 females, 9 males) accepted to participate (mean age 72.0 years ±